Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Merged with Biogen in $5.3 Billion Deal
Summary
Apellis Pharmaceuticals, Inc. has completed its merger with Biogen Inc., resulting in Apellis becoming a wholly owned subsidiary of Biogen. The merger, valued at approximately $5.3 billion, involved the exchange of Apellis' common stock for $41.00 per share in cash and contingent value rights (CVRs). The transaction also included the conversion of Apellis' outstanding warrants, options, and restricted stock units into cash and CVRs. As a result of the merger, Apellis' board of directors resigned, and its certificate of incorporation and bylaws were amended. Additionally, the merger triggered a Fundamental Change under Apellis' existing debt indenture, affecting the conversion rights and repurchase rights of its note holders.
Profitelligence Alerts
Get alerts for APLS
Be first to know when Apellis Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Official SEC Documents
Advertisement